Skip to main content
NEO logo

NEO · Neogenomics Inc · Documents

Track NEO — free
Market Cap
$1.98B
Shares
129.39M
Volume · Nov 18 1.09M Avg daily vol (3M) 1.96M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $727.33M up 10.1% 10-K filed Feb 17, 2026 Quarterly report FY2026 Q3 Revenue $209.25M up 11.4% 10-Q filed Oct 28, 2026 Latest results Third-quarter revenue rises 11% to $209 million; guidance raised 8-K filed Oct 28, 2026 Earnings call Q3 2026 earnings call Held Oct 28, 2026
2026
Oct 28
Earnings call
Raises Revenue and EBITDA Guidance; Warren Stone Named CEO

Neogenomics reported total revenue of $209 million, up 11% year over year, ahead of its expectations of approximately 10% growth. It raised full-year revenue guidance to $807 to $809 million from $802 to $806 million, and adjusted EBITDA guidance to approximately 60 million from 56 to 58 million. Warren Stone becomes chief executive officer effective January 4, 2027, succeeding Tony Zook, who becomes executive chair.

Read from the first part of this long document
5 source passages
Total revenue grew to $209 million, up 11% year-over-year and ahead of our expectations of approximately 10% growth. we are raising our full-year 26 revenue guidance to a range of $807 to $809 million, up from $802 to $806 million discussed previously we are raising our full year 26 adjusted EBITDA guidance to approximately 60 million versus 56 to 58 million discussed previously effective January 4, 2027, Warren Stone, our current president and chief operating officer, will become chief executive officer of Neogenomics and join our board. I'll support this transition and remain actively involved as our new executive chair. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth and gross margin expansion strengthen results

NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.

Revenue $209.25M ▲ 11.4% Net loss $7.55M
Read from the MD&A section
3 source passages
NeoGenomics, Inc., a Nevada corporation Revenue for the three and nine months ended September 30, 2026 increased $21.5 million or 11.4%, and increased $60.4 million or 11.2%, respectively, as compared to 2025. Gross profit margin for the three and nine months ended September 30, 2026 was 46.2% and 45.1%, respectively, compared to 42.8% and 43.0% in the same periods of 2025. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter revenue rises 11% to $209 million; guidance raised

NeoGenomics reported third-quarter 2026 revenue up 11% to $209 million. It raised full-year 2026 revenue guidance to $807 million to $809 million and expects adjusted EBITDA of approximately $60 million. Warren Stone, President and COO, will become CEO effective January 4, 2027.

Financial results
5 source passages
Consolidated revenue for the third quarter of 2026 was $209 million, an increase of 11% over the same period in 2025. The Company is revising its full-year 2026 guidance, as shown below (in millions). | Consolidated revenue | $727 | $802 | $806 | $807 | $809 | 11% | 11% | | Adjusted EBITDA | $43 | $56 | $58 | Approximately $60 | | Approximately 38% | | Announced planned leadership succession in which Warren Stone, President and COO, will become CEO and Board member effective January 4, 2027. Open the document at this passage
Jul 28
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $201.66M ▲ 11.2% Net income $2.24M
Jun 17
Current report 8-K
Other events AI summary on its way
Jun 15
Current report 8-K
Other events AI summary on its way
Apr 28
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $186.67M ▲ 11.1% Net loss $17.11M
Feb 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $727.33M ▲ 10.1% Net loss $108.03M
2025
Showing 1–50 of 187 documents
Key facts CIK 1077183 CUSIP 64049M209 13F (30d) 301 filings 280 filers Visit website Investor relations